Top Markets
Coin of the day
Mural Oncology plc Mural Oncology plc

Mural Oncology plc

MURA
Rank in Stocks #27064
Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and... Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects centered on modified interleukin-18 and tumor-specific interleukin-12. Incorporated in 2017, Mural Oncology maintains its headquarters in Dublin, Ireland. By November 15, 2023, the company had transitioned from being a subsidiary of Alkermes plc.
Share Price
$2.04
Last synced: 2025-12-09
Market Cap
$35.38M
Change (1 day)
0.00%
Change (1 year)
-2.39%
Country
IE
Trade Mural Oncology plc (MURA)

Category

Earnings for Mural Oncology plc (MURA)
Earnings in 2026 TTM: 0
According to Mural Oncology plc latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Mural Oncology plc from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$5.27B -
US
$-3.09B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH